HALOG-E Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Halog-e, and when can generic versions of Halog-e launch?
Halog-e is a drug marketed by Sun Pharm Inds Inc and is included in one NDA.
The generic ingredient in HALOG-E is halcinonide. There are seven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the halcinonide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Halog-e
A generic version of HALOG-E was approved as halcinonide by MYLAN on August 12th, 2019.
Summary for HALOG-E
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 67 |
| Patent Applications: | 5,100 |
| DailyMed Link: | HALOG-E at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for HALOG-E
US Patents and Regulatory Information for HALOG-E
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharm Inds Inc | HALOG-E | halcinonide | CREAM;TOPICAL | 018234-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
